VYNE Therapeutics Reports Second Quarter 2022 Financial Results Bridgewater, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2022. During…
Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes What is Cerevel Therapeutics? Cerevel Therapeutics Holdings, Inc. is a company based in Cambridge, Massachusetts that is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. Their mission is to develop innovative treatments for conditions that affect the brain…
The Influence of Brent Donnelly’s am/FX Introduction Brent Donnelly’s am/FX is a highly regarded resource in the global markets community, providing valuable insights on a daily basis. His in-depth analysis on various topics related to global markets has gained him a loyal following among traders and investors. What am/FX Covers Brent covers a wide range…
MetaFi: The Future of Finance? A Conversation with Vladmir Gorbunov From CeFi to DeFi: The Evolution of Choise.com Welcome, readers, to another exciting installment of Finance Magnates interviews! Today, we have the pleasure of sitting down with Vladimir Gorbunov, the dynamic CEO of Choise.com. If you’re not familiar with Choise.com, let me break it down…
Welcome to the Future of Body Contouring with AirSculpt Technologies, Inc. Embracing Innovation and Excellence As AirSculpt Technologies, Inc. announces its impressive second quarter results for 2022, it is evident that the company is paving the way for the future of premium body contouring procedures. With a commitment to excellence and innovation, AirSculpt continues to…
THE LONDON OPENING 12-08-2022 European Equities Opened Around Parity After a Mixed Asian Session European equities opened this morning around parity after Wall Street’s heavy retracement from yesterday’s highs and after a mixed Asian session, where the ChinaA50 index rose 0.7%, and the ASX200 fell 0.62%. The exception was… The Quirky World of Financial Markets…
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® Introduction Hey there, readers! Today we’re diving into some exciting news from Agios regarding the publication of Phase 2 data in The Lancet. The data showcases the safety and efficacy of PYRUKYND® in adults with non-transfusion-dependent α- or β-thalassemia….
Welcome to the Johnson Fistel Blog! Breaking News: Marqeta Shareholder Investigation San Diego, Aug. 11, 2022 – Johnson Fistel, LLP, a leading shareholder rights law firm, has announced an investigation into Marqeta, Inc. The firm is looking into whether there have been any violations of securities laws by the Company, its executive officers, or other…
